Ikeda Jun-ichi, Yao Kozo, Matsubara Masahiro
Department of Pharmacology and Molecular Biology, Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Biol Pharm Bull. 2006 Nov;29(11):2222-5. doi: 10.1248/bpb.29.2222.
Chronic hypertension shifts cerebral blood flow (CBF) autoregulation towards higher blood pressure. We examined whether or not benidipine, a long-lasting dihydropyridine calcium channel blocker (CCB), improves the CBF autoregulation in spontaneously hypertensive rats (SHRs). CBF was analyzed by laser-Doppler flowmetry during stepwise hypotension by controlled bleeding. The lower limit of CBF autoregulation was calculated as the mean arterial blood pressure at which CBF decreased by 10% of the baseline. Mean arterial blood pressure and cerebral vascular resistance in SHRs were higher than those in normotensive Wistar rats. Oral administration of benidipine (3 mg/kg) for 8 d lowered the mean arterial blood pressure and cerebral vascular resistance, which were equivalent to the effects of amlodipine (3 mg/kg), another CCB, or candesartan (1 mg/kg), an Angiotensin II type-1 receptor blocker. The lower limit of CBF autoregulation in SHRs (142+/-4 mmHg) was significantly shifted to a higher-pressure level compared with Wistar rats (59+/-2 mmHg). The lower limit of CBF autoregulation was significantly lower in the benidipine-treated group (91+/-4 mmHg) than that in the control SHRs, and similar to that of the amlodipine group (97+/-6 mmHg). Benidipine reduced the lower limit of CBF autoregulation more effectively than candesartan (109+/-4 mmHg). In conclusion, benidipine shifted the limit of CBF autoregulation towards lower blood pressure in SHRs under hypotensive conditions by hemorrhage. These results suggest that benidipine may be useful for the treatment of hypertensive patients with the elderly or cerebrovascular disorders, in whom autoregulation of CBF is impaired.
慢性高血压会使脑血流量(CBF)自身调节向更高血压偏移。我们研究了长效二氢吡啶类钙通道阻滞剂(CCB)贝尼地平是否能改善自发性高血压大鼠(SHR)的CBF自身调节。通过控制性放血使血压逐步降低期间,用激光多普勒血流仪分析CBF。CBF自身调节的下限计算为CBF降至基线值的10%时的平均动脉血压。SHR的平均动脉血压和脑血管阻力高于正常血压的Wistar大鼠。口服贝尼地平(3mg/kg)8天可降低平均动脉血压和脑血管阻力,其效果与另一种CCB氨氯地平(3mg/kg)或血管紧张素II 1型受体阻滞剂坎地沙坦(1mg/kg)相当。与Wistar大鼠(59±2mmHg)相比,SHR的CBF自身调节下限(142±4mmHg)显著向更高压力水平偏移。贝尼地平治疗组的CBF自身调节下限(91±4mmHg)显著低于对照SHR组,与氨氯地平组(97±6mmHg)相似。贝尼地平比坎地沙坦(109±4mmHg)更有效地降低了CBF自身调节下限。总之,在出血性低血压条件下,贝尼地平使SHR的CBF自身调节下限向更低血压偏移。这些结果表明,贝尼地平可能对患有CBF自身调节受损的老年人或脑血管疾病的高血压患者有用。